The evolution of hypertension treatment has seen the introduction of sophisticated drug classes, among which Angiotensin II Receptor Blockers (ARBs) have become cornerstones. Azilsartan medoxomil, a prodrug of Azilsartan, exemplifies the advancements in this area, offering potent and sustained blood pressure control. NINGBO INNO PHARMCHEM CO.,LTD. is a key supplier of high-quality Azilsartan medoxomil, supporting the pharmaceutical sector's development of effective antihypertensive therapies.
The therapeutic efficacy of Azilsartan is unlocked through its prodrug form, azilsartan medoxomil. Upon oral administration, azilsartan medoxomil undergoes rapid hydrolysis by esterases in the gastrointestinal tract and during absorption. This process converts it into the active metabolite, azilsartan, which then exerts its pharmacological effects. Understanding the azilsartan medoxomil mechanism of action is crucial for appreciating its bioavailability and therapeutic delivery. This bioactivation ensures that the body receives the active compound efficiently, leading to consistent blood pressure reduction.
As an ARB, azilsartan medoxomil, via azilsartan, effectively blocks the actions of angiotensin II at the AT1 receptor. This blockade prevents the vasoconstriction and sodium retention typically induced by angiotensin II, leading to a decrease in blood pressure. The potency of Azilsartan in this regard has made it a valuable therapeutic option for patients with hypertension. The consistent control of blood pressure offered by Azilsartan contributes significantly to reducing the long-term risk of cardiovascular events, such as strokes and heart attacks, underscoring the importance of azilsartan for hypertension management.
The pharmacokinetic properties of azilsartan medoxomil are characterized by its rapid absorption and efficient conversion to azilsartan. The drug's elimination half-life and its minimal impact on bioavailability when taken with food further enhance its clinical utility. These attributes, combined with the general Angiotensin II Receptor Blocker benefits, make Azilsartan a preferred choice for many patients. NINGBO INNO PHARMCHEM CO.,LTD. ensures that our supply of Azilsartan medoxomil meets stringent quality standards, enabling reliable drug formulation.
In considering the comprehensive use of Azilsartan and its prodrug, awareness of safety aspects is vital. This includes understanding potential azilsartan drug interactions and strictly adhering to azilsartan pregnancy warnings. The potential risks associated with renin-angiotensin system-acting drugs during pregnancy necessitate careful patient management and the consideration of alternative treatments when appropriate.
NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to providing the pharmaceutical industry with high-purity Azilsartan and its prodrugs. By ensuring the quality and reliability of our APIs, we contribute to the development of effective treatments that improve cardiovascular health globally. Our commitment is to support the advancements in pharmacotherapy for conditions like hypertension.
Manufacturing Facilities






Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.